Synthetic Cathinones and Their Rewarding and Reinforcing Effects in Rodents by Watterson, Lucas (Author) et al.
Review Article
Synthetic Cathinones and Their Rewarding and Reinforcing
Effects in Rodents
Lucas R. Watterson and M. Foster Olive
Department of Psychology, Arizona State University, P.O. Box 871104, Tempe, AZ 85287-1104, USA
Correspondence should be addressed to M. Foster Olive; foster.olive@asu.edu
Received 12 March 2014; Accepted 16 May 2014; Published 4 June 2014
Academic Editor: Eduardo Puelles
Copyright © 2014 L. R. Watterson and M. F. Olive. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Synthetic cathinones, colloquially referred to as “bath salts,” are derivatives of the psychoactive alkaloid cathinone found in Catha
edulis (Khat). Since the mid-to-late 2000s, these amphetamine-like psychostimulants have gained popularity amongst drug users
due to their potency, low cost, ease of procurement, and constantly evolving chemical structures. Concomitant with their increased
use is the emergence of a growing collection of case reports of bizarre and dangerous behaviors, toxicity to numerous organ systems,
and death. However, scientific information regarding the abuse liability of these drugs has been relatively slower to materialize.
Recently we have published several studies demonstrating that laboratory rodents will readily self-administer the “first generation”
synthetic cathinonesmethylenedioxypyrovalerone (MDPV) andmethylone via the intravenous route, in patterns similar to those of
methamphetamine. Under progressive ratio schedules of reinforcement, the rank order of reinforcing efficacy of these compounds
is MDPV ≥ methamphetamine > methylone. MDPV and methylone, as well as the “second generation” synthetic cathinones 𝛼-
pyrrolidinovalerophenone (𝛼-PVP) and 4-methylethcathinone (4-MEC), also dose-dependently increase brain reward function.
Collectively, these findings indicate that synthetic cathinones have a high abuse and addiction potential and underscore the need
for future assessment of the extent and duration of neurotoxicity induced by these emerging drugs of abuse.
1. The Rise of Synthetic Cathinone
Use and Abuse
In 2007, a new class of designer drugs known as synthetic
cathinones emerged in Europe. Soon afterwards, reports of
synthetic cathinone use, abuse, toxicity, and death began to
surface in USA [1–12]. The rise of synthetic cathinone use
in USA was alarmingly rapid, with poison control centers
receiving 0, 304, and 6156 calls reporting synthetic cathinone
toxicity in the years 2009–2011, respectively [13]. Approxi-
mately 98% of synthetic cathinones first identified in toxico-
logical investigationswere primarily 4-methylmethcathinone
(4-MMC, mephedrone), 3,4-methylenedioxypyrovalerone
(MDPV), and 3,4-methylenedioxymethcathinone (methy-
lone) [1–12], but as discussed below, many additional syn-
thetic cathinones have since surfaced.
Synthetic cathinones are chemical derivatives of cathi-
none, a naturally occurring amphetamine-like alkaloid found
in the Catha edulis (Khat) shrub. Khat has been utilized
for centuries by indigenous peoples of the Horn of Africa
and Arabian Peninsula for its stimulant properties [14].
However, due to its high abuse liability, cathinone is clas-
sified as a Schedule I controlled substance in USA. In an
attempt by manufacturers and distributors to evade the
attention of regulatory and law enforcement agencies, syn-
thetic cathinones are falsely marketed and sold as innocuous
retail products such as “bath salts,” “plant food,” “research
chemicals,” and “glass cleaner,” to name a few. Synthetic
cathinones are also often sold under brand names such as
“Ivory Wave” and “Vanilla Sky” and are usually labeled “not
for human consumption” or “for research purposes only”
[15]. These packages typically consist of one or multiple
synthetic cathinones and are often mixed with other sub-
stances such as caffeine, topical anesthetics, binding and
cutting agents, and even other illicit drugs [11, 16]. Regardless
of the marketing tactic employed, synthetic cathinones are
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ultimately intended for use as “legal high” alternatives to illicit
psychostimulants such as cocaine, methamphetamine, and
3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”)
[1–12, 17–20].
For synthetic cathinone users, desired psychological
effects include increased energy, libido, empathy, eupho-
ria, alertness, and well-being. However, numerous serious
adverse effects are associated with synthetic cathinone use
[1–12]. Psychological and behavioral complications include
confusion, panic, persistent hallucinations and delusions,
agitated paranoia, and aggression and violence including
suicide, homicide, and infanticide. Synthetic cathinone use
is also associated with toxicity of multiple organ systems,
sometimes referred to as the “sympathomimetic toxidrome”
[7], including chest pain, nausea, vomiting, seizures, hyper-
tension, tachycardia, hyperthermia, cardiac arrest, and death.
Despite the high risk of these adverse effects, users of
synthetic cathinones frequently report a persistent desire
to continue use of these drugs, and prolonged periods of
synthetic cathinone use have been reported [2, 3, 6, 8,
12, 21–27], suggesting a high potential for addiction and
dependence.
2. Chemistry and Pharmacology of
Synthetic Cathinones
The chemical structure of cathinone is strikingly similar to
that of D-amphetamine (Figure 1), with cathinone differing
only in the presence of a ketone oxygen atom (C=O) on the
𝛽 position of the side chain. However, as recently pointed out
by Glennon [28], some synthetic cathinones have chemical
structures that are entirely novel such that the amphetamine
analogs upon which they are based have received little if
any scientific study. As mentioned above, during the initial
detection of these drugs in USA, approximately 98% of all
synthetic cathinones encountered by law enforcement were
either mephedrone, MDPV, or methylone (see Figure 1 for
chemical structures). Citing an imminent threat to public
health, the U.S. Department of Justice temporarily placed
mephedrone, MDPV, and methylone into Schedule I status
in October, 2011, which was followed by permanent clas-
sification of mephedrone and MDPV as such in August
2012 [29]. Methylone remained under temporary scheduling
status pending further collection of data and information and
was permanently placed into Schedule I status in April 2013
[30].
Synthetic cathinones are considered “designer drugs”
since their chemical structure can be easily altered by as
few as one or two atoms to create new chemical entities.
Due to the ease with which synthetic cathinones can be
chemically modified to create unique chemical entities,
over 40 other synthetic cathinones have been identified
in clandestine drug markets [28], including the “second
generation” synthetic cathinones naphyrone (naphthylpy-
rovalerone), 3-fluoromethcathinone (3-FMC), methedrone
(4-methoxymethcathinone), 𝛽-keto-N-methylbenzodioxol-
ylbutanamine (bk-MBDB, butylone), 𝛽-keto-methylbenzo-
dioxolylpentanamine (bk-MBDP, pentylone), 4-methyl-N-
ethylcathinone (4-MEC), 4-methyl-pyrrolidinopropiophe-
none (4-MePPP), 𝛼-pyrrolidinopentiophenone (𝛼-PVP), 2-
methylamino-1-phenylpentan-1-one (pentedrone), and 4-
fluoro-N-methylcathinone (4-FMC, flephedrone). Many of
these were placed into temporary Schedule I status in Febru-
ary 2014 while additional data on abuse liability are collected
[31].
Synthetic cathinones exert their psychostimulant and
sympathomimetic effects either by promoting the release
of monoamine neurotransmitters (dopamine, DA; nore-
pinephrine, NE; and serotonin, 5-HT) via reversal of plasma
membrane monoamine transporters or by inhibiting the
reuptake of monoamines from the synaptic cleft [32–42].The
resulting excessive monoamine levels in the synaptic cleft
lead to overstimulation of postsynaptic DA, NE, and 5-HT
receptors in the brain and periphery, which results in their
psychological, behavioral, and toxic effects.These neurophar-
macological actions of synthetic cathinones are remarkably
similar to those of more traditional illicit psychostimu-
lants, such as cocaine (a monoamine reuptake inhibitor
with high affinity for DA versus other plasma membrane
monoamine transporters), D-amphetamine and metham-
phetamine (monoamine releasers with higher affinity for DA
and NE versus 5-HT), and MDMA (a monoamine releaser
with a higher affinity for 5-HT versus other plasma mem-
brane monoamine transporters). It is becoming increasingly
apparent that, like traditional psychostimulants, different
synthetic cathinones have diverse mechanisms of action [28].
For example, mephedrone is a broad spectrum monoamine
releasing agent [32, 33, 35, 38, 39, 41], MDPV is a long-acting
inhibitor of plasma membrane DA and NE transporters [33,
41, 43], andmethylone is a monoamine releasing agent with a
higher affinity for plasma membrane 5-HT transporters [32,
38, 41]. Although studies on “second generation” synthetic
cathinones are few, thus far it appears that these newer
analogues have similar neurochemical actions [38, 41, 44, 45].
3. Laboratory Rodents Readily Self-Administer
MDPV and Methylone
The intravenous self-administration (IVSA) model is gen-
erally considered to be the “gold standard” of preclinical
paradigms for assessing the abuse liability of psychoactive
compounds. Our laboratory routinely uses this paradigm in
rats to assess the potential therapeutic efficacy of pharma-
cological compounds as potential antiaddiction medications,
and we have recently utilized this paradigm to assess the
potential abuse liability of synthetic cathinones [46, 47].
In this procedure, first an indwelling intravenous catheter
is surgically implanted into the jugular vein while the other
end is tunneled under the skin and connected to a vascular
access port implanted under the skin and exiting between
the scapulae. Following recovery from surgery, the animal
is placed in a drug self-administration chamber equipped
with two levers that are interfaced with a computer and a
syringe pump (see Figure 2). A sterile drug solution (such
as MDPV or methylone dissolved in physiological saline) is
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Figure 1: Similar chemical structures of cathinone, D-amphetamine, and methamphetamine (top row), the “first generation” synthetic
cathinones mephedrone, MDPV, and methylone (middle row), and the “second generation” synthetic cathinones 𝛼-PVP and 4-MEC.
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Figure 2: The rat intravenous self-administration paradigm for assessment of the abuse liability of synthetic cathinones. Upon pressing of
one of two levers (designated the active lever) in an operant self-administration chamber (center), a computer-controlled syringe pump (left)
delivers a solution containing MDPV or methylone to an indwelling venous catheter via infusion tubing connected to a liquid swivel. Each
drug infusion is accompanied by simultaneous presentation of tone and illumination of a stimulus light located above the lever. Presses on the
opposite lever (designated the inactive lever) have no consequences but are recorded to ensure establishment of correct response contingency
of drug delivery.The graph on the right represents typical response patterns across daily experimental sessions during the acquisition of drug
self-administration.
placed in a syringe and delivered by a computer-controlled
syringe pump located outside the apparatus. The syringe is
connected to a single-channel liquid swivel, which allows
free rotation of the animal while maintaining a continuous
flow of the drug solution. In addition to the two response
levers, stimulus lights and a speaker provide visual and
auditory cues during drug infusions. Presses on one of the
levers designated the “active” lever result in a computer-
controlled drug infusion and simultaneous brief presentation
of auditory and visual cues. Presses on the other “inactive”
lever have no programmed consequences at any time during
the experiment (as a control for nonspecific behavior). To
avoid overdose or toxicity due to multiple drug infusions in
close temporal proximity, immediately following each drug
infusion a “timeout” period is introduced (∼20 sec), whereby
additional active lever presses do not result in additional drug
infusions. Drug self-administration sessions are typically 2–
6 hr in length and are conducted daily, 7 days per week.
There are many advantages of intravenous self-admin-
istration procedures as a model for human drug-taking
behavior, including the following: (1) the drug is admin-
istered voluntarily by the animal (as opposed to passive
administration by the experimenter); (2) it is administered
directly into the bloodstream mimicking intravenous drug
use in humans and results in rapid brain penetrance; (3)
drug-taking behavior can be temporally examined within
and between self-administration sessions; (4) the effects of
candidate therapeutic pharmacological compounds or other
experimental manipulations on drug self-administration can
be determined; and (5) the number of responses that must
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be exerted by the animal in order to receive a drug infusion
(called the “ratio”) can be increased exponentially (called a
“progressive ratio” procedure) until the animal “gives up” and
no longer performs the operant task (called the “breakpoint”).
This latter method is used to measure the level of motivation
to self-administer the drug as well as the efficacy of the rein-
forcer. In addition, when given longer daily access (i.e., 6 hr
ormore per session) to psychostimulants with high addiction
potential, rats will gradually and significantly escalate their
daily drug intake. This escalated drug intake is a cardinal
feature of the transition from drug abuse to addiction, and a
sustained enhancement in drug intake produces dysregulated
brain stress and executive control systems that parallel clinical
observations of drug addicts [48–50]. Moreover, extended
access to drugs with lower abuse liability generally do not
result in escalation of intake, and drug intake patterns usually
remain episodic [51].
Recently, our laboratory has demonstrated robust intra-
venous self-administration of MDPV and methylone in
laboratory rats [46, 47]. When tested for self-administration
of MDPV under limited access conditions (daily ses-
sions that were 2 hr in length), rats readily acquired self-
administration of MDPV at all doses tested (0.05, 0.1, and
0.2mg/kg/infusion). Under a progressive ratio schedule of
reinforcement, which requires an exponentially increasing
number of lever presses to obtain each subsequent drug
infusion within a single test session (i.e., 1 lever press for
the first infusion, 2 for the second, 4 for the third, and
so on), a positive relationship between MDPV dose and
breakpoints for drug reinforcement was observed, suggesting
that higher doses of MDPV are associated with increasing
reinforcer efficacy and motivation to obtain the drug. By
comparison, responding for a low dose of methamphetamine
(0.05mg/kg/infusion) produced breakpoints that were sim-
ilar in magnitude to the same dose of MDPV. When the
length of the self-administration session was increased to
6 hr/day, we observed an escalation of drug intake over time
for the 0.1 and 0.2mg/kg/infusion doses of MDPV, with the
highest dose producing the most robust escalation of intake
that was similar in magnitude to the 0.05mg/kg/infusion
dose of methamphetamine. When rats were tested for self-
administration of methylone under limited access conditions
[46], rats did not display robust self-administration for the
lowest dose of methylone tested (0.05mg/kg/infusion) but
readily self-administered higher doses of methylone (0.1, 0.2,
and 0.5mg/kg/infusion). However, unlikeMDPV, methylone
did not lead to escalation of intake under extended access
conditions for any dose tested. This is particularly intrigu-
ing since methylone is a 𝛽-ketone derivative of MDMA,
and self-administration of this parent drug also does not
reliably produce escalation of intake under extended access
conditions [52–54], which is perhaps also reflective of its
preferential affinity for plasma membrane serotonin versus
dopamine transporters. Despite the lack of escalation, and
underscoring the dangers of synthetic cathinone use, 2 rats
in the highest methylone dose group (0.5mg/kg/infusion)
self-administered the drug to the point of seizure and
death during a 6 hr session, and similar case reports of
methylone-induced deaths in humans have been reported
[55–58]. Finally, as with MDPV, we observed a positive
relationship between methylone dose and breakpoints for
self-administration under progressive ratio conditions.These
findings indicate that MDPV and methylone are readily
self-administered intravenously by laboratory rats and are
in agreement with studies from other laboratories showing
that MDPV, as well as the synthetic cathinone mephedrone,
is self-administered intravenously by rodents [35, 59–61].
In addition, our studies indicate that escalated intake of
synthetic cathinones, a cardinal feature of addiction, can also
be observed in laboratory rodents.
4. Synthetic Cathinones Increase Brain
Reward Circuit Function
It is well accepted that drugs of abuse exert their rewarding
(euphorigenic) and reinforcing effects via interactions with
brain reward circuitry [62–65]. This circuitry, known as
the mesocorticolimbic pathway, is primarily comprised of
dopaminergic neurons in the ventral tegmental area (VTA)
that project rostrally to form the medial forebrain bundle
(MFB) in the lateral hypothalamus and form dopaminergic
synapses in forebrain regions including the nucleus accum-
bens (NAc) and prefrontal cortex (PFC). However, confine-
ment of the neural basis of drug reward and reinforcement
to this singular dopaminergic pathway is overly simplis-
tic, as many studies have indicated that other ascending
monoaminergic fibers that form the MFB, such as nora-
drenergic neurons from the locus coeruleus and serotonergic
neurons from the raphe nuclei, also contribute to brain
reward function [64, 66–69].
A widely used method for assessing functional activity
of the brain reward circuitry in behaving animals is the
intracranial self-stimulation (ICSS) paradigm [68, 70–73]. In
this procedure, which is depicted in Figure 3, a laboratory
animal (typically a rat or mouse) performs an operant
response such as nose poke, lever press, or rotation of a wheel
manipulandum in order to receive a short pulse of electrical
current via a chronically implanted electrode into a specific
brain region, typically the MFB. The implanted electrode is
connected to a computer-controlled current generator via
an electrical commutator. The animal quickly learns that
the operant response reliably leads to electrical stimulation
of the reward circuitry that presumably produces subjective
pleasurable effects, and in our experience rats will exert up to
several thousand ICSS responses in a 30min period [46, 47].
Different laboratories use a variety of stimulation parameters
such as varying the intensity of the current delivered (𝜇A),
duration of pulses (msec), frequency of electrical pulse as
a function of pulse/interpulse interval, and the waveform
of pulses [74]. However, the two most extensively used
ICSS paradigms in evaluating abuse liability of psychoactive
compounds are the rate-frequency curve-shift procedure [75]
and the discrete-trial current threshold intensity procedure
[74, 76, 77], the latter of which is utilized by our laboratory
[46, 47, 51].
In the discrete-trials current threshold procedure, follow-
ing acquisition of operant responding, discrete-trial training
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Figure 3: The ICSS paradigm for assessment of the ability of synthetic cathinones to affect brain reward function. Upon pressing of one
of two levers (designated the active lever) in an operant self-administration chamber (right), a computer-controlled current generator (left)
delivers pulses of electrical current to an indwelling bipolar electrode implanted into the MFB. Current can be delivered to the electrode at
various intensities and frequencies in a variety of paradigms involving multiple trials in order to determine baseline and drug-induced shifts
in current intensity thresholds or frequency response curves. See text for further details.
begins where each trial is initiated with a “free” (nonresponse
contingent) stimulation, followed by an intertrial interval
(ITI, average 7.5 sec) where responses yield no programmed
consequences. After the ITI, an operant response yields
stimulation identical to the free stimulation. Once animals
learn to inhibit responding during the ITI, baseline current
intensity threshold training begins. These procedures begin
at a predetermined level of current intensity (i.e., 120 𝜇A).
Trials are conducted in blocks (3 to 5 trials each), consisting of
a free stimulation, ITI, and response-contingent stimulation
and current intensity that remain the same for the entire
block. Correct responding on the majority of trials results
in a lowering of the current intensity by a fixed increment
(e.g., 5 𝜇A) for the next block of trials, whereas failure to
correctly respond to most trials results in an increase in
the current intensity by the same increment for the next
trial block. This stimulation titration procedure progresses
through 2 ascending and 2 descending series of current
intensities. Across these 2 ascending and descending series,
ICSS thresholds are calculated as the mean (in 𝜇A) across
blocks that do or do not support responding. Thus, ICSS
thresholds represent the minimum current intensity at which
the animal will reliably respond for electrical stimulation
of the MFB. Following stabilization of ICSS thresholds
across several days of testing, a dose of a candidate drug
of abuse (such as a synthetic cathinone) is administered
prior to a test session. In our laboratory, we assess changes
in current intensity thresholds across a range of doses of
each drug in a semirandom counterbalanced design, with
multiple determinations at each dose to provide increased
reliability of changes in current threshold intensities (see
[46, 47, 51] for details). Resulting decreases in ICSS thresholds
(relative to baseline or saline administration) are indicative
of hedonic rewarding effects of the drug (i.e., less current
is required to activate the reward circuitry due to prior
activation by the drug administered), whereas elevations
in ICSS thresholds are indicative of aversive or dysphoric
effects (i.e., more current is required to activate the reward
circuitry due to the aversive nature of the drug administered).
ICSS procedures have been used for over 50 years and have
consistently revealed that nearly all drugs that are abused by
humans, including psychostimulants, lower ICSS thresholds
[51, 71, 74–76].
We have recently assessed the ability of acute systemic
administration of the “first generation” synthetic cathinones
MDPV [47] and methylone [46] to alter ICSS thresholds in
laboratory rats. For MDPV, we found that all doses tested
(0.1, 0.5, 1, and 2mg/kg) produced significant reductions in
ICSS thresholds (∼20–40%) compared with those following
saline administration, with the most robust effects observed
after the 1mg/kg dose. We observed far less robust effects
following administration of methylone, with doses of 0.1 and
0.5mg/kg producing no effects on ICSS thresholds, whereas
higher doses (1, 3, 5, and 10mg/kg) produced reductions in
ICSS thresholds ranging from ∼5 to 15% in parallel with
increasing doses.These less robust effects ofmethylone versus
MDPV on ICSS thresholds indicate that methylone may
be less potent in activating brain reward circuit function,
which could be attributable to its higher affinity for serotonin
versus dopamine transporters [32, 38] and is likely related
to the lack of escalated intake in extended access during
self-administration. This reduced activation of brain reward
circuitry by methylone, as compared to classical psychostim-
ulants such as methamphetamine, has also been observed
following administration of MDMA [78], the amphetamine
analog ofmethylone, which also possesses a similar 5-HT/DA
transporter affinity ratio [32].
We have also recently conducted a study on the potential
ICSS threshold-lowering effects of the “second generation”
synthetic cathinones 𝛼-PVP and 4-MEC [79]. When rats
were administered 𝛼-PVP (0.1, 0.3, 1, or 5mg/kg), significant
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reductions (∼14–20%) in ICSS thresholds were observed
following the 0.3 and 1mg/kg doses. When rats were admin-
istered 4-MEC (0.3, 1, 3, 10, 30, or 100mg/kg), significant
reductions (∼10–15%) in ICSS thresholds were observed
following the 10 and 30mg/kg doses. However, for both
drugs, the highest doses tested produced increases (∼19% for
𝛼-PVP at 5mg/kg and∼28% for 4-MECat 100mg/kg) in ICSS
thresholds, suggesting aversive effects of these high doses.
Our ICSS studies confirm reports by other laboratories that
synthetic cathinones activate brain reward circuitry [80, 81].
5. Conclusions and Future Directions
We have demonstrated that laboratory rats will voluntarily
self-administer the “first generation” synthetic cathinones
MDPV and methylone via the intravenous route. Further-
more,MDPV, but notmethylone, leads to escalation of intake
following extended access to the drug. We also have demon-
strated that MDPV and methylone, as well as the “second
generation” synthetic cathinones 𝛼-PVP and 4-MEC, lower
current intensity thresholds for ICSS, indicating activation of
brain reward circuitry. Along with existing case reports and
preliminary epidemiological studies in humans [1–12], these
findings clearly indicate that synthetic cathinones possess
a significant abuse liability and potential for addiction and
should be considered an emerging class of abused drugs that
warrant appropriate legislative control and the development
of interventions for detoxification and treatment.
However, numerous questions regarding the effects of
synthetic cathinones on the brain still remain to be answered.
For example, do synthetic cathinones possess affinity for
any molecular entities other than monoamine transporters
whichmight contribute to their neurobiological or behavioral
effects? What are the mechanisms underlying the persistent
psychotomimetic effects of synthetic cathinones?What is the
feasibility of utilizing cognitive-behavioral, pharmacological,
or other approaches for treating dependence on synthetic
cathinones? What are the lasting effects of synthetic cathi-
nones on neuronal plasticity and function, gliotransmission,
cerebrovascular function, cell viability, gene expression, and
epigenetic processes? Answers to this latter question are
being actively pursued by our laboratory. Specifically, we
are currently conducting studies on the effects of synthetic
cathinone self-administration on macrostructural changes
and neurotoxicity in the brain, with the ultimate goal of
identifying potential mechanisms and treatment avenues for
reversing lasting deleterious effects of synthetic cathinones
in the brain. The field of synthetic cathinone research is
only in its infancy, and while initial legislative efforts have
attempted to curb the availability and use of these drugs of
abuse, it is clear that manymore “designer drugs” of this drug
class (and others) will continue to evolve numerous steps
ahead of policymakers, scientists, educators, and treatment
professionals alike.
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